Briefs, Companies,

Sothema: third-quarter revenue up 24%

According to its press release, Sothema posted consolidated revenue of MAD 940 million in the third quarter of 2026, up 24%. Over nine months, revenue reached MAD 2,736 million (+19%).

Sothema published its third-quarter indicators on 17 November 2026.

Consolidated revenue for the quarter reached MAD 940 million, compared with MAD 757 million a year earlier (+24%). Over the first nine months, it came to MAD 2,736 million, against MAD 2,306 million (+19%). According to the release, growth came from chronic disease treatments and ophthalmology, as well as the subsidiaries Axess Pharma (oncology) and Soludia (dialysis).

Capital expenditure reached MAD 130 million at end-September, compared with MAD 49 million a year earlier, notably for the acquisition of a brand’s rights in Morocco. Consolidated net debt fell 9% compared with end-2025.

Read the profile of Sothema

Source: Sothema, communiqué financier T3 2026 (via Médias24), November 17, 2026.

General information only. Nothing on this site constitutes investment advice or a recommendation to buy or sell.